Price
$12.84+7.72%Social Signal Score
Analyst Ratings
36 analystsRevenue
$988.60M-6.87%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Albert A. Manzone
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 8,100
- Beta
- 0.54
- Country
- IE
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -0.39
Financials
Revenue
$988.60M-6.9%Net Income
$-27.50MEBITDA
$101.60MFree Cash Flow
$78.70MEPS (diluted)
$-0.20Shares Outstanding (diluted)
139.40M-2.7%Operating Expenses
$293.60MCash & Debt
$436.60MReturn of Capital
$40.20MRevenue by Segment (annual)
$4.25BDividend per Share
$0.29Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.25B | $-1.43B | $-10.29 |
| 2024 | $4.37B | $-171.80M | $-1.25 |
| 2023 | $4.66B | $-12.70M | $-0.09 |
| 2022 | $4.45B | $-140.60M | $-0.97 |
| 2021 | $4.14B | $-68.90M | $-0.98 |
| 2020 | $4.09B | $-162.60M | $-1.19 |
| 2019 | $3.87B | $146.10M | $1.07 |
| 2018 | $4.73B | $131.00M | $0.95 |
| 2017 | $4.95B | $119.60M | $0.84 |
| 2016 | $5.28B | $-4.01B | $-28.01 |
| 2014 | $4.60B | $127.90M | $0.92 |
| 2013 | $4.06B | $205.30M | $1.78 |
| 2012 | $3.54B | $441.90M | $4.71 |
| 2011 | $3.17B | $401.61M | $4.31 |
Valuation
PRGOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+66.67%Social Signal Score
Mentions (17)
- Newsprnewswire.com·11d ago·Neutral
Perrigo to Attend the Jefferies Miami Consumer Conference DUBLIN, Nov. 11, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that Interim President and CEO Albert Manzone and CFO Eduardo Bezerra are scheduled to participate in investor meetings at the Jefferies Miami Consumer Conference on Wednesday, November 18, 2026. About Perrigo Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and …
View source ↗ - Newsmarketbeat.com·14d ago·Negative
Perrigo Q3 Earnings Call Highlights Perrigo NYSE: PRGO reported lower third-quarter sales and earnings as cautious retailer inventory decisions and weakness in Europe weighed on results, even as the self-care company gained market share and narrowed its core sales decline.
View source ↗ - Newsfool.com·16d ago·Positive
Perrigo: 3 Key Takeaways for Long-Term Investors Perrigo agreed to divest its infant formula business. U.S. e-commerce reached 22% of Perrigo's U.S. volume.
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Perrigo Company plc (PRGO) Q3 2026 Earnings Call Transcript Perrigo Company plc ( PRGO ) Q3 2026 Earnings Call November 4, 2026 8:30 AM EST Company Participants Eric Jacobson - Vice President of Global Investor Relations Albert Manzone - Interim President, Interim CEO & Director Eduardo Bezerra - Executive VP & CFO Conference Call Participants Susan Anderson - Canaccord Genuity Corp., Research Division Ethan Brown - JPMorgan Chase & Co, Research Division Presentation Operator Good morning ladies…
View source ↗ - Newszacks.com·18d ago·Positive
Perrigo (PRGO) Surpasses Q3 Earnings Estimates Perrigo (PRGO) came out with quarterly earnings of $0.6 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.8 per share a year ago.
View source ↗ - Newsprnewswire.com·18d ago·Neutral
…o reflect divestiture, more measured retailer inventory positioning, and continued softness in Europe DUBLIN, Nov. 4, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading provider of consumer self-care products, today announced financial results from continuing operations for the third quarter ended September 26, 2026. "Our Three-S plan is delivering continued progress in the areas of the business within our control," said Albert Manzone, Interim Presiden…
View source ↗ - Newsprnewswire.com·24d ago·Neutral
Perrigo Announces Quarterly Dividend DUBLIN, Oct. 29, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that its Board of Directors has approved a quarterly dividend of $0.29 per share, or $1.16 per share on an annualized basis. The cash dividend is payable on December 15, 2026, to shareholders of record on November 27, 2026.
View source ↗ - Newsprnewswire.com·24d ago·Negative
…apabilities will support the continued supply of safe, high-quality, and affordable infant nutrition DUBLIN, Oct. 29, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or "the Company"), a leading provider of consumer self-care products, today announced that it has entered into a definitive agreement pursuant to which MeridianMade, an American contract manufacturing platform dedicated to infant nutrition, will acquire Perrigo's Infant Formula business for total consideration of up…
View source ↗ - Newsprnewswire.com·32d ago·Neutral
Perrigo to Release Third Quarter 2026 Financial Results on November 4, 2026 DUBLIN, Oct. 21, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that it plans to release its third quarter 2026 financial results on Wednesday, November 4, 2026. The company will hold a conference call beginning at 8:30 a.m.
View source ↗ - Newszacks.com·58d ago·Neutral
Perrigo (PRGO) Moves 6.1% Higher: Will This Strength Last? Perrigo (PRGO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
View source ↗ - Newsdefenseworld.net·58d ago·Negative
Squarepoint Ops LLC Cuts Position in Perrigo Company plc $PRGO Squarepoint Ops LLC reduced its stake in shares of Perrigo Company plc (NYSE: PRGO) by 95.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,900 shares of the company's stock after selling 443,842 shares during the quarter.
View source ↗ - Newszacks.com·79d ago·Neutral
Perrigo (PRGO) Up 13.8% Since Last Earnings Report: Can It Continue? Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsprnewswire.com·87d ago·Neutral
Perrigo to Attend the Barclays Global Consumer Conference DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that Interim President and CEO Albert Manzone and CFO Eduardo Bezerra are scheduled to participate in investor meetings at the Barclays Global Consumer Conference on Thursday, September 10th, 2026. About Perrigo Perrigo Company plc is a leading pure-play self-care company with over a century of exp…
View source ↗ - Newszacks.com·88d ago·Negative
PRGO or NEOG: Which Is the Better Value Stock Right Now? Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two stocks is more attractive to value investors?
View source ↗ - Newsseekingalpha.com·101d ago·Positive
Perrigo: The Rebound Is Just Getting Started Perrigo Company remains substantially undervalued, with a Buy rating justified by strong income and growth potential. Recent quarterly EPS and revenue beats, coupled with market share gains, signal improving fundamentals despite a soft OTC market. Management's focus on cost control, debt reduction, and dividend growth underpins a compelling 16–21% expected annual total return.
View source ↗ - Newszacks.com·104d ago·Positive
PRGO vs. NEOG: Which Stock Is the Better Value Option? Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two companies is the best option for those looking for undervalued stocks?
View source ↗ - Newsmarketbeat.com·106d ago·Neutral
Perrigo Q2 Earnings Call Highlights Perrigo NYSE: PRGO reported second-quarter 2026 results that exceeded its internal earnings expectations, while sales declined amid soft consumer self-care categories, retailer inventory reductions and a slower start to seasonal demand. The company maintained its full-year outlook, citing improving category trends, market-share gains and expected second-half contributions from innovation, distribution and demand-generation efforts.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $0.77 per share
Typical surprise +7.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$0.60 vs $0.51beat
- Wed, Aug 5$0.50 vs $0.39beat
- Wed, May 6$0.43 vs $0.39beat
- Thu, Feb 26$0.77 vs $0.80miss
- Wed, Nov 5$0.80 vs $0.75beat
- Wed, Aug 6$0.57 vs $0.59miss
Estimates and results for PRGO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PRGO officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (47d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (20d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (44d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (27d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (27d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (26d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (26d later)Sell$50,001 - $100,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (48d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (47d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (48d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (44d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (20d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (21d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (21d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (23d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 19, 2023 (23d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jun 22, 2023 (36d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jun 22, 2023 (41d later)Sell$100,001 - $250,000
- Michael T. McCaulhouse · TX10 · disclosed Jun 22, 2023 (35d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jun 22, 2023 (36d later)Sell$50,001 - $100,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
